0001193125-20-194796 Sample Contracts

EXECUTIVE EMPLOYMENT AGREEMENT

Executive Employment Agreement • July 17th, 2020 • Checkmate Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Massachusetts

• Contract Type
  Executive Employment Agreement
• Filed
  July 17th, 2020
• Company
  Checkmate Pharmaceuticals, Inc.
• Industry
  Biological products, (no disgnostic substances)
• Jurisdiction
  Massachusetts

This Employment Agreement (the “Agreement”), made and entered into this 14th day of July, 2015 (the “Effective Date”), by and between Checkmate Pharmaceuticals, Inc., a Delaware corporation (“Company”), and Arthur M. Krieg (“Executive”).

CERTAIN INFORMATION IDENTIFIED BY BRACKETED ASTERISKS ([* * *]) HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. LICENSE AGREEMENT

License Agreement • July 17th, 2020 • Checkmate Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York

• Contract Type
  License Agreement
• Filed
  July 17th, 2020
• Company
  Checkmate Pharmaceuticals, Inc.
• Industry
  Biological products, (no disgnostic substances)
• Jurisdiction
  New York

THIS LICENSE AGREEMENT (the “Agreement”) is dated as of June 17, 2015 (the “Signing Date”) by and between Cytos Biotechnology Ltd. a Swiss company having a place of business at Wagistrasse 25, 8952 Schlieren, Switzerland (“Licensor”), and Checkmate Pharmaceuticals, LLC, having its registered office at 49 Trowbridge St. #3, Cambridge, MA 02138, USA (“Checkmate”). Licensor and Checkmate may be referred to herein as a “Party” or, collectively, as “Parties”.

Contract

Service Agreement • July 17th, 2020 • Checkmate Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Massachusetts

• Contract Type
  Service Agreement
• Filed
  July 17th, 2020
• Company
  Checkmate Pharmaceuticals, Inc.
• Industry
  Biological products, (no disgnostic substances)
• Jurisdiction
  Massachusetts

The licensee(s) identified on the signature page of this agreement (the “Licensee” or “Client”) and CIC hereby agree to the following (the “Agreement” or “Service Agreement”).

CERTAIN INFORMATION IDENTIFIED BY BRACKETED ASTERISKS ([* * *]) HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. AMENDMENT NO. I TO LICENSE AGREEMENT

License Agreement • July 17th, 2020 • Checkmate Pharmaceuticals, Inc. • Biological products, (no disgnostic substances)

• Contract Type
  License Agreement
• Filed
  July 17th, 2020
• Company
  Checkmate Pharmaceuticals, Inc.
• Industry
  Biological products, (no disgnostic substances)

THIS AMENDMENT NO I (the Amendment) is made as of August 15, 2017 (the Amendment Effective Date) by and between KUROS BIOSCIENCES AG (formerly Cytos Biotechnology, LTD), a company registered in Switzerland whose registered office is at Wagistrasse 25, 8952 Schlieren, Switzerland (“Licensor”), and CHECKMATE PHARMACEUTICALS, INC., having its registered office at One Broadway, 14lh Floor, Cambridge, MA 02142, USA, (“Checkmate”). Licensor and Checkmate may be referred to herein as a “Party” or, collectively, as “Parties”.